NCT05588284 (PREFER) is a NA clinical trial of AngioJet device in Acute Deep Venous Thrombosis of Femoral Vein (Disorder), sponsored by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University.

What drugs are being tested in NCT05588284?

Interventions in NCT05588284: AngioJet device, anticoagulation alone.

What condition does NCT05588284 study?

NCT05588284 studies Acute Deep Venous Thrombosis of Femoral Vein (Disorder).

Is NCT05588284 still recruiting?

NCT05588284 is currently enrolling by invitation. Last updated 14 May 2025.

Last reviewed 2025-05-14 · How we verify

NCT05588284: PREFER

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Preservation of Venous Valvular Function After PMT for Acute DVT

ENROLLING BY INVITATION NA Last updated 14 May 2025

What this trial tests

NA trial testing AngioJet device in Acute Deep Venous Thrombosis of Femoral Vein (Disorder) in 100 participants. Enrolling by invitation.

Timeline

6 June 2022

Primary endpoint
6 June 2025

6 June 2025

Quick facts

Lead sponsor	Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Phase	NA
Status	ENROLLING BY INVITATION
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	100
Start date	6 June 2022
Primary completion	6 June 2025
Estimated completion	6 June 2025
Sites	7 locations across China

Drugs / interventions tested

AngioJet device
anticoagulation alone

Conditions studied

Acute Deep Venous Thrombosis of Femoral Vein (Disorder) — all drugs for Acute Deep Venous Thrombosis of Femoral Vein (Disorder) →

Sponsor

Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University

Who can join

Adults 18 to 80, any sex, with Acute Deep Venous Thrombosis of Femoral Vein (Disorder). Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

To evaluate the venous valvular function after pharmacomechanical thrombectomy (PMT) for acute femoral-popliteal venous thrombosis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University trials

Trials by the same sponsor.

NCT07535567 — Postoperative Radiotherapy With Nimotuzumab ± Benmelstobart in Intermediate-Risk Head and Neck Squamous Cell Carcinoma: · Phase 2, PHASE3 · not yet recruiting
NCT07505251 — Development and Validation of the Periodontal Map Derived From IOS and CBCT Registration for Diagnosis and Treatment Pla · not yet recruiting
NCT07466810 — Resection and Defect Repair of Oral Cancer Aided by Mixed Reality Technology · NA · not yet recruiting
NCT07533695 — Impact of Day 2 Versus Day 3 Fresh Embryo Transfer on Live Birth Rate in Poor-Prognosis Patients · NA · not yet recruiting
NCT07490561 — The Impact of Assisted Hatching on Pregnancy Outcomes After Vitrified-Warmed Embryo Transfer in Advanced-age Patients · NA · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05588284 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
Last refreshed: 14 May 2025

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05588284.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing